Status:
UNKNOWN
Intralesional Vitamin D in Alopecia Areata
Lead Sponsor:
Alexandria University
Conditions:
Alopecia Areata
Eligibility:
All Genders
10+ years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the efficacy and safety of intralesional injection of vitamin D3 versus intralesional injection of corticosteroids in treatment of alopecia areata. this will be carried out on 40 patients...
Eligibility Criteria
Inclusion
- Site: scalp. Extent: localized alopecia areata (less than 50% scalp involvement).
Exclusion
- Other skin diseases affecting the scalp
- Pregnant or lactating women.
- Bleeding or coagulation disorders
- Immunocompromised patients.
- Known hypersensitivity to vitamin D3.
- Patients who received systemic or topical treatment for alopecia areata in the last month.
- Patients taking vitamin D supplements in the last 6 months.
- Patients treated with topical vitamin D analogues.
- Patients with diseases known to alter vitamin D level as autoimmune diseases, liver or renal diseases.
- Obesity (defined as body mass index ≥ 25).
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04660786
Start Date
November 1 2021
End Date
December 1 2022
Last Update
July 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Alexandria, Egypt, 21521